Madrigal Pharmaceuticals, Inc. (MDGL)

NMS – Цена в реальном времени. Валюта: USD

510.26

+13.23 (2.66%)

При закрытии: May 12, 2026, 4:00 PM EDT

510.00

-0.26 (-0.05%)

До открытия: May 13, 2026, 6:26 AM EDT

07.05.2026

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on May 1, 2026 to 47 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan.

07.05.2026

Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up

MDGL stock up on better-than-expected first-quarter results on account of robust Rezdiffra sales, driven by strong MASH demand and rising patient adoption.

06.05.2026

Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2026 Earnings Call Transcript

06.05.2026

Madrigal (MDGL) Reports Q1 Loss, Beats Revenue Estimates

Madrigal (MDGL) came out with a quarterly loss of $3.25 per share versus the Zacks Consensus Estimate of a loss of $3.61. This compares to a loss of $3.32 per share a year ago.

06.05.2026

Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates

CONSHOHOCKEN, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports first-quarter 2026 financial results and provides corporate updates.

05.05.2026

Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline

Company advances its leadership in MASH with clinical-stage, genetically targeted siRNA asset from Arrowhead Pharmaceuticals Precision approach targets patients who have a mutation in the PNPLA3 gene, which is highly prevalent among Hispanic patients with MASH Phase 1 data published in The New England Journal of Medicine demonstrated a 46% liver fat reduction in homozygous patients and a well-tolerated safety profile Madrigal's pipeline includes more than 10 programs at multiple stages of development, anchored by Rezdiffra ® (resmetirom) as the foundational treatment CONSHOHOCKEN, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced an exclusive global license agreement with Arrowhead Pharmaceuticals for ARO-PNPLA3, a clinical-stage, small interfering RNA (siRNA) asset targeting patatin-like phospholipase domain-containing protein 3 (PNPLA3), a key genetic driver of MASH.

05.05.2026

Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced an exclusive worldwide license agreement with Madrigal Pharmaceuticals (NASDAQ: MDGL) for ARO-PNPLA3, Arrowhead's clinical stage RNA interference (RNAi) therapeutic designed to reduce liver expression of patatin-like phospholipase domain containing 3 (PNPLA3) as a potential treatment for patients with metabolic dysfunction-associated steatohepatitis (MASH). “The early clinical data for ARO-PNPLA3 h.

Видео

08.08.2025

Positive

Madrigal Pharmaceuticals CEO: We're positioned for decades of growth

Пресс-релизы

07.05.2026

Madrigal Pharmaceuticals, Inc. (MDGL)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Madrigal Pharmaceuticals, Inc. (MDGL)

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up

Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2026 Earnings Call Transcript

Madrigal (MDGL) Reports Q1 Loss, Beats Revenue Estimates

Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates

Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline

Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals

Видео

Пресс-релизы

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up

Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2026 Earnings Call Transcript

Madrigal (MDGL) Reports Q1 Loss, Beats Revenue Estimates

Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates

Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline

Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals

Видео

Пресс-релизы

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates

Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline

Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals

Search stocks

Madrigal Pharmaceuticals, Inc. (MDGL)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Madrigal Pharmaceuticals, Inc. (MDGL)

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up

Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2026 Earnings Call Transcript

Madrigal (MDGL) Reports Q1 Loss, Beats Revenue Estimates

Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates

Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline

Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals

Видео

Пресс-релизы

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up

Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2026 Earnings Call Transcript

Madrigal (MDGL) Reports Q1 Loss, Beats Revenue Estimates

Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates

Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline

Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals

Видео

Пресс-релизы

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates

Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline

Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals